Transparency notification – Gilead holds 25.10% of Galapagos shares
November 13 2019 - 4:01PM
Transparency notification – Gilead holds 25.10% of Galapagos shares
Mechelen, Belgium; 13 November
2019; 22.01 CET; regulated information – Galapagos NV (Euronext
& NASDAQ: GLPG) received a transparency notification from
Gilead Sciences, Inc.
Pursuant to Belgian transparency legislation1,
Galapagos received a transparency notification on 11 November 2019
from Gilead Sciences, Inc. (acting as a parent undertaking or a
controlling person), who notified that Gilead Therapeutics A1
Unlimited Company, an indirect subsidiary of Gilead Sciences, Inc.,
holds 16,207,477 of Galapagos' voting rights, consisting of
16,207,477 shares, as a result of subscribing to a capital increase
in the framework of the exercise of the Initial Warrant A and thus
receiving 2,617,791 new Galapagos shares on 6 November 2019. This
represents 25.10% of Galapagos' currently outstanding 64,571,622
shares. Gilead Therapeutics A1 Unlimited Company thus crossed above
the 25% threshold of Galapagos' voting rights by acquisition of
voting securities on 6 November 2019.
The notification specifies furthermore that (i)
Gilead Therapeutics A1 Unlimited Company is a direct subsidiary of
Gilead Biopharmaceutics Ireland UC, (ii) Gilead Biopharmaceutics
Ireland UC is a direct subsidiary of Gilead Sciences, Inc., and
(iii) Gilead Sciences, Inc. has no controlling shareholder.
The full transparency notification is available
on the Galapagos website.
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG)
discovers and develops small molecule medicines with novel modes of
action, three of which show promising patient results and are
currently in late-stage development in multiple diseases. The
Company's pipeline comprises Phase 3 through to discovery programs
in inflammation, fibrosis, osteoarthritis and other indications.
Galapagos' ambition is to become a leading global biopharmaceutical
company focused on the discovery, development and commercialization
of innovative medicines. More information at www.glpg.com.
Galapagos
Contacts |
|
Investors: |
Media: |
Elizabeth
Goodwin |
Carmen
Vroonen |
VP Investor
Relations |
Senior Director
Communications |
+1 781 460
1784 |
+32 473 824
874 |
|
|
Sofie Van
Gijsel |
Evelyn Fox |
Director Investor
Relations |
Director
Communications |
+32 485 19 14
15 |
+31 6 53 591
999 |
ir@glpg.com |
communications@glpg.com |
1 Belgian Act of 2 May 2007 on the disclosure of
major shareholdings in issuers whose shares are admitted to trading
on a regulated market and regarding miscellaneous provisions.
Galapagos (EU:GLPG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Sep 2023 to Sep 2024